Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-05-28 Sale | 2025-06-16 3:40 pm | AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner | 200,000 | $1.09 | $218,000 | 3,017,432 (Indirect) | View |
| 2025-06-02 Purchase | 2025-06-03 4:46 pm | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 10,000 | $1.0665 | $10,665 | 1,516,262 (Indirect Direct) | View |
| 2025-05-28 Sale | 2025-05-30 5:40 pm | AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner | 2,532,000 | $1.1345 | $2,872,477 | 3,217,432 (Indirect) | View |
| 2025-05-28 Purchase | 2025-05-29 4:17 pm | AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director | 8,610 | $1.1769 | $10,133 | 8,610 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 8:02 pm | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 2,957 | $1.341 | $3,965 | 32,670 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 8:00 pm | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 2,957 | $1.341 | $3,965 | 29,824 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 7:57 pm | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 2,029 | $1.341 | $2,721 | 33,313 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 7:57 pm | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 9,663 | $1.341 | $12,958 | 116,672 (Direct) | View |
| 2024-12-06 Purchase | 2024-12-10 8:46 pm | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 60,000 | $1.4451 | $86,708 | 652,573 (Indirect) | View |
| 2024-11-26 Purchase | 2024-11-27 7:07 pm | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 75,000 | $1.4091 | $105,685 | 622,573 (Indirect) | View |
| 2024-11-27 Purchase | 2024-11-27 4:16 pm | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 2,000 | $1.4 | $2,800 | 531,079 (Indirect Direct) | View |
| 2024-11-19 Purchase | 2024-11-21 6:00 pm | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 200,000 | $1.0656 | $213,128 | 514,788 (Indirect) | View |
| 2024-11-18 Purchase | 2024-11-20 4:11 pm | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 25,000 | $1.0018 | $25,046 | 529,079 (Indirect Direct) | View |
| 2024-11-18 Purchase | 2024-11-18 8:51 pm | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 50,000 | $0.9994 | $49,970 | 1,361,012 (Indirect Direct) | View |
| 2024-08-14 Purchase | 2024-08-14 8:24 pm | AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner | 1,500,000 | $1.04 | $1,560,000 | 5,749,432 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-05-22 Option Award | 2025-05-23 5:04 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 5:03 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:59 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:58 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:57 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:56 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:51 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-05-22 Option Award | 2025-05-23 4:51 pm | N/A 2035-05-21 | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 19,111 | $0 | 19,111 (Direct) | View |
| 2025-04-10 Option Award | 2025-04-11 5:08 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 10,523 | $0 | 551,418 (Direct) | View |
| 2025-04-10 Option Award | 2025-04-11 5:03 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 9,705 | $0 | 2,392,177 (Direct) | View |
| 2025-04-10 Option Award | 2025-04-11 4:57 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 3,065 | $0 | 6,231 (Direct) | View |
| 2025-04-10 Option Award | 2025-04-11 4:55 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 9,705 | $0 | 41,507 (Direct) | View |
| 2025-02-26 Option Award | 2025-02-28 4:27 pm | N/A 2035-02-25 | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 150,750 | $0 | 180,574 (Direct) | View |
| 2025-02-26 Option Award | 2025-02-28 4:26 pm | N/A 2035-02-25 | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 139,500 | $0 | 172,170 (Direct) | View |
| 2025-02-26 Option Award | 2025-02-28 4:22 pm | N/A 2035-02-25 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 175,500 | $0 | 292,172 (Direct) | View |
| 2025-02-26 Option Award | 2025-02-28 4:22 pm | N/A 2035-02-25 | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 435,750 | $0 | 1,796,762 (Direct) | View |
| 2025-02-26 Option Award | 2025-02-28 4:19 pm | N/A 2035-02-25 | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 84,000 | $0 | 117,313 (Direct) | View |
| 2024-12-19 Option Award | 2024-12-23 6:42 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 3,166 | $0 | 3,166 (Direct) | View |
| 2024-12-19 Option Award | 2024-12-23 6:40 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 8,972 | $0 | 2,382,472 (Direct) | View |
| 2024-12-19 Option Award | 2024-12-23 6:38 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 8,972 | $0 | 31,802 (Direct) | View |
| 2024-12-19 Option Award | 2024-12-23 6:33 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 9,816 | $0 | 540,895 (Direct) | View |
| 2024-12-19 Option Award | 2024-12-23 6:32 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 9,077 | $0 | 1,243,938 (Direct) | View |
| 2024-11-04 Option Award | 2024-11-05 4:57 pm | N/A 2034-11-03 | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 30,375 | $0 | 55,592 (Direct) | View |
| 2024-11-04 Option Award | 2024-11-05 4:51 pm | N/A 2034-11-03 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 94,500 | $0 | 189,335 (Direct) | View |
Ownership | 2024-11-05 4:49 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 0 | $0 | 135,417 (Direct) | View |